TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
||||
1. Identity of the issuer or the underlying issuer |
Circassia Pharmaceuticals PLC |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
|
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
||||
An event changing the breakdown of voting rights |
X |
||||
Other (please specify): |
|
|
|||
3. Full name of person(s) subject to the |
OppenheimerFunds, Inc. |
||||
4. Full name of shareholder(s) |
|
||||
5. Date of the transaction and date on |
13 January 2015 |
||||
6. Date on which issuer notified: |
14 January 2015 |
||||
7. Threshold(s) that is/are crossed or |
10% (increased to 11.00%) |
||||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
GB00BJVD3B28 |
10,805,820 |
10,805,820 |
20,839,269 |
|
20,839,269 |
|
11.00% |
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
20,839,269 |
11.00% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
OppenheimerFunds, Inc. ("OFI") is a registered investment advisor with the U.S. SEC. Its ultimate parent company, Massachusetts Mutual Life Insurance Company, qualifies for disaggregation under FCA regulations. The shares of the issuer are held by investment accounts managed by OFI. |
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
|
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Julien Cotta (Chief Financial Officer) |
|
15. Contact telephone number: |
+ 44 (0) 1 865 405560 |
|